{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-26-001048","form_type":"8-K","ticker":"APYX","cik":"0000719135","company_name":"Apyx Medical Corp","filed_at":"2026-01-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:37.544565+00:00","generated_at":"2026-05-16T10:59:11.824846+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Apyx Medical reports preliminary Q4 revenue up ~34% YoY; Surgical Aesthetics up 38%","bullets":["Total Q4 revenue expected $19.0-19.2M, up ~34% YoY; FY revenue $52.7-52.9M, up ~10%.","Surgical Aesthetics Q4 revenue $16.6-16.8M (+38% YoY); U.S. Surgical Aesthetics up ~51% on AYON launch.","OEM Q4 revenue $2.4M (+13% YoY); FY OEM revenue $7.5M (-21% YoY).","CEO cites AYON momentum and GLP-1-driven demand for loose skin procedures.","Full financial results to be reported in March 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-001048","json":"https://secwatch.observer/filing/0001437749-26-001048.json","markdown":"https://secwatch.observer/filing/0001437749-26-001048.md","text":"https://secwatch.observer/filing/0001437749-26-001048.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/719135/000143774926001048/0001437749-26-001048-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/719135/000143774926001048/apyx20260108_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T10:59:11.824846+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}